Australian cancer diagnostics company Rhythm Biosciences (ASX:RHY) has appointed Gavin Fox-Smith as its new Chair, following the retirement of Otto Buttula at the company’s Annual General Meeting.
Mr Buttula’s planned retirement was first announced in June, marking the conclusion of a tenure that saw Rhythm transition from an emerging biotechnology company to a commercial-stage diagnostics enterprise. The Board thanked him for his leadership, describing his contributions as pivotal to the company’s growth and transformation.
Mr Fox-Smith, a highly regarded industry executive and company director, brings extensive leadership experience across healthcare, technology and innovation sectors. He has previously held senior roles with Johnson & Johnson, the Medical Technology Association of Australia, and other industry bodies, and currently serves on several corporate and non-profit boards.
“I am honoured to take on the role of Chairman at such an exciting time for Rhythm,” Mr Fox-Smith said. “On behalf of the Board, I extend our deepest thanks to Otto for his dedication and vision. I look forward to working with the Board and management team to continue building on the company’s strong foundation and driving ultimate value for shareholders.”
Rhythm Biosciences is developing and commercialising ColoSTAT, a simple, blood-based test designed to detect colorectal cancer (CRC) through the measurement of five specific protein biomarkers. The company describes the technology as an affordable and accessible alternative for individuals who are unable or unwilling to participate in traditional screening programs.
Colorectal cancer is the second leading cause of cancer-related deaths globally, but it is highly curable if detected early. Rhythm aims to make ColoSTAT a key tool in reducing mortality and healthcare costs associated with bowel cancer.
Founded in 2017 and headquartered in Melbourne, Rhythm Biosciences is also exploring broader applications of its diagnostic and genetic technologies through partnerships and international distribution initiatives.